You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Hot Topics in Neuromuscular Disorders: A Spotlight on Myasthenia Gravis

  • Authors: Vera Bril, MD, BSc, FRCPC; Hans D. Katzberg, MD, MSc, FAAN; Carolina Barnett-Tapia, MD, PhD; Nicholas J. Silvestri, MD, FAAN
  • CME / CE Released: 9/29/2023
  • Valid for credit through: 9/29/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    Nurses - 1.00 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    IPCE - 1.00 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for neurologists, primary care physicians, nurses, nurse practitioners, and physician assistants involved in the care of patients with neurologic conditions.

The goal of this activity is that learners will be better able to diagnose, monitor ongoing disease activity, and optimize treatment approaches based on newly available data in patients with generalized myasthenia gravis.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Diagnosis of MG
    • Clinical tools that can be used to assess ongoing disease activity in patients with MG
    • Pivotal clinical trial data for therapies studied for the management of MG


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Vera Bril, MD, BSc, FRCPC

    Professor of Medicine (Neurology)
    Director, Ellen and Martin Prosserman Center for Neuromuscular Diseases
    Toronto General Hospital, University Health Network
    University of Toronto
    Toronto, Ontario, Canada

    Disclosures

    Vera Bril, MD, BSc, FRCPC, has the following relevant financial relationships:
    Consultant or advisor for: Akcea Therapeutics; Alnylam Pharmaceuticals, Inc; ArgenX; AstraZeneca Pharmaceuticals LP-Alexion Pharmaceuticals, Inc.; CSL Behring; Grifols; Ionis Pharmaceuticals; Janssen; Momenta Pharmaceuticals, Inc.; Novo Nordisk; Roche; Sanofi; Takeda; UCB Pharma, Inc.
    Research funding from: Akcea Therapeutics; ArgenX; AstraZeneca Pharmaceuticals LP-Alexion Pharmaceuticals, Inc.; CSL Behring; Grifols; Immunovant, Inc.; Ionis Pharmaceuticals; Octapharma; Takeda; UCB Pharma, Inc.
    Contracted researcher for: ArgenX; Grifols; Takeda

  • Hans D. Katzberg, MD, MSc, FAAN

    Associate Professor of Medicine (Neurology)
    Ellen and Martin Prosserman Center for Neuromuscular Diseases
    Clinician Investigator, Krembil Research Institute
    University Health Network, University of Toronto
    Toronto, Ontario, Canada

    Disclosures

    Hans D. Katzberg, MD, MSc, FAAN, has the following relevant financial relationships:
    Consultant or advisor for: Alexion Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc; ArgenX; CSL Behring; Merz Pharmaceuticals; Octapharma; Roche; Syneos; UCB Pharma, Inc.
    Research funding from: Roche; Takeda

  • Carolina Barnett-Tapia, MD, PhD

    Associate Professor of Neurology
    Division of Neurology
    Institute of Health Policy, Management and Evaluation
    Dalla Lana School of Public Health
    University of Toronto
    Toronto, Ontario, Canada

    Disclosures

    Carolina Barnett-Tapia, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Alexion Pharmaceuticals, Inc.; ArgenX; Janssen; Sanofi
    Research funding from: AstraZeneca Pharmaceuticals LP; Grifols

  • Nicholas J. Silvestri, MD, FAAN

    Professor of Neurology​
    Department of Neurology
    Jacobs School of Medicine & Biomedical Sciences​
    University at Buffalo​
    Buffalo, New York, United States

    Disclosures

    Nicholas J. Silvestri, MD, FAAN, has the following relevant financial relationships:
    Consultant or advisor for: Alexion Pharmaceuticals, Inc.; ArgenX; UCB Pharma, Inc.
    Speaker or member of speakers bureau for: Alexion Pharmaceuticals, Inc.; ArgenX

Editor

  • Meg Monday

    Senior Director, Content Development, Medscape, LLC

    Disclosures

    Meg Monday has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Hot Topics in Neuromuscular Disorders: A Spotlight on Myasthenia Gravis

Authors: Vera Bril, MD, BSc, FRCPC; Hans D. Katzberg, MD, MSc, FAAN; Carolina Barnett-Tapia, MD, PhD; Nicholas J. Silvestri, MD, FAANFaculty and Disclosures

CME / CE Released: 9/29/2023

Valid for credit through: 9/29/2024, 11:59 PM EST

processing....

Contents of This CME Activity

To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Key Elements for ​the Diagnosis of ​Myasthenia Gravis

Antibody status, electrophysiologic tests, and neurologic exam -- do you have the right tools in your toolbox for MG diagnosis?
Hans D. Katzberg, MD, MSc, FAAN

Updates on Patient-Reported Outcomes and the Clinical Assessment of Myasthenia Gravis

Natural fatigability and fluctuations make clinical assessment in MG difficult -- what's the best validated measure for your practice?
Carolina Barnett-Tapia, MD, PhD

A Review of Pivotal Clinical Trial Data for MG Therapeutics

Novel immunotherapies are changing the treatment landscape in MG -- do you know how to individualize treatment for your patients?
Vera Bril, MD, BSc, FRCPC

How Much Do We Know About the Long-Term Effects of MG​ Therapeutics?

Join Dr Silvestri for an expert review of available data on old and new MG treatment strategies.
Nicholas J. Silvestri, MD, FAAN
 

Learning Feedback Questions

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

  • Print